Dataset: Definition and characterization of the systemic T cell dysregulation in untreated indolent B cell lymphoma and very early CLL
Epidemiological data show that the immune system may control or promote emergence and growth of a neoplastic lymphomatous clone....
Epidemiological data show that the immune system may control or promote emergence and growth of a neoplastic lymphomatous clone. Conversely, systemic lymphomas, especially myeloma and CLL, are associated with clinical immunodeficiency. This prospective controlled study demonstrates substantially reduced circulating T helper cells, predominantly naive CD4+ cells, in patients with non-leukemic follicular and extranodal marginal zone lymphomas, but not in monoclonal gammopathy and early CLL. These numerical changes were correlated with a preactivated phenotype, hyperreactivity in vitro, presenescence, and a Th2 shift of peripheral T helper cells. No prominent alterations were found in the regulatory T cell compartment. Gene expression profiling of in vitro-stimulated CD4+ cells revealed an independent second alteration of T helper cell physiology which was most pronounced in early CLL but also detectable in FL/eMZL. This pattern consisted of downregulation of proximal and intermediate T-cell receptor signaling cascades and globally reduced cytokine secretion. Both types of T cell dysfunction may contribute to significant immunodeficiency in non-leukemic indolent B-cell lymphomas as demonstrated by refractoriness to hepatitis B vaccination. The precise definition of systemic T cell dysfunction serves as the basis to study its prognostic impact, its relationship to the established influence of the lymphoma microenvironment, and its therapeutic manipulation 8 samples from FL/eMZL patients, 7 samples from CLL patients, 5 samples of MGUS patients, 5 MALT, 16 healthy controls
- Species:
- human
- Samples:
- 41
- Source:
- E-GEOD-23293
- PubMed:
- 21270444
- Updated:
- Dec.12, 2014
- Registered:
- Sep.15, 2014
Sample | DISEASE STATE | USED IN CLL VS HEALTHY COMPARISON (1-YES) | AGE IN YEARS | USED IN FL/EMZL VS HEALTHY COMPARISON (1-YES) | USED IN MGUS VS HEALTHY COMPARISON (1-YES) |
---|---|---|---|---|---|
GSM571720 | healthy | 1 | 41 | 1 | 0 |
GSM57172 | FL | 0 | 65 | 1 | 0 |
GSM571722 | CLL | 1 | 53 | 0 | 0 |
GSM571723 | MALT | 0 | 65 | 1 | 0 |
GSM571724 | FL | 0 | 51 | 1 | 0 |
GSM571725 | FL | 0 | 37 | 1 | 0 |
GSM571726 | CLL | 1 | 72 | 0 | 0 |
GSM571727 | MALT | 0 | 77 | 1 | 0 |
GSM571728 | FL | 0 | 60 | 1 | 0 |
GSM571729 | FL | 0 | 66 | 1 | 0 |
GSM571730 | CLL | 1 | 54 | 0 | 0 |
GSM57173 | CLL | 1 | 42 | 0 | 0 |
GSM571732 | CLL | 1 | 60 | 0 | 0 |
GSM571733 | MGUS | 0 | 55 | 0 | 1 |
GSM571734 | MGUS | 0 | 43 | 0 | 1 |
GSM571735 | MALT | 0 | 49 | 1 | 0 |
GSM571736 | FL | 0 | 64 | 1 | 0 |
GSM571737 | MGUS | 0 | 50 | 0 | 1 |
GSM571738 | CLL | 1 | 74 | 0 | 0 |
GSM571739 | CLL | 1 | 66 | 0 | 0 |
GSM571740 | MGUS | 0 | 66 | 0 | 1 |
GSM57174 | healthy | 0 | 51 | 0 | 1 |
GSM571742 | healthy | 0 | 43 | 1 | 1 |
GSM571743 | healthy | 1 | 60 | 0 | 1 |
GSM571744 | MALT | 1 | 56 | 0 | 1 |
GSM571745 | healthy | 0 | 65 | 1 | 0 |
GSM571746 | healthy | 0 | 63 | 1 | 0 |
GSM571747 | healthy | 1 | 65 | 1 | 1 |
GSM571748 | healthy | 1 | 51 | 1 | 1 |
GSM571749 | healthy | 0 | 64 | 1 | 0 |
GSM571750 | healthy | 1 | 76 | 1 | 0 |
GSM571749 | healthy | 0 | 64 | 1 | 0 |
GSM571752 | healthy | 1 | 70 | 1 | 0 |
GSM571753 | healthy | 0 | 62 | 1 | 0 |
GSM571749 | healthy | 0 | 64 | 1 | 0 |
GSM571755 | MGUS | 0 | 59 | 0 | 1 |
GSM571756 | FL | 0 | 42 | 1 | 0 |
GSM571757 | MALT | 0 | 35 | 1 | 0 |
GSM571758 | healthy | 0 | 49 | 1 | 1 |
GSM571759 | FL | 0 | 68 | 1 | 0 |
GSM571760 | healthy | 0 | 36 | 1 | 0 |